High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
Abstract Carbohydrate antigen 19‐9 (CA19‐9) fails to demonstrate the predictive value for early detection pancreatic ductal adenocarcinoma (PDAC). Glypican‐1 (GPC1+) exosomes may serve as a noninvasive diagnostic tool to detect early stages of PDAC. Therefore, it is necessary to explore the serum GP...
Main Authors: | Cong‐ya Zhou, Yi‐ping Dong, Xiao Sun, Xin Sui, Hong Zhu, Ya‐qin Zhao, Yuan‐yuan Zhang, Clifford Mason, Qing Zhu, Su‐xia Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-11-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1833 |
Similar Items
-
Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
by: Juan Zhao, et al.
Published: (2022-10-01) -
Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
by: Yongfeng Xu, et al.
Published: (2022-05-01) -
Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study
by: Ankang Wang, et al.
Published: (2020-03-01) -
Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01) -
Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
by: Andrea N. Riner, et al.
Published: (2020-06-01)